Industry: Pharmaceuticals, Biotechnology
About AGTC: AGTC is developing novel therapeutics for patients with unmet medical needs utilizing the non-pathogenic adeno-associated virus. AGTC’s first product candidate is a treatment for Alpha One Antitrypsin Deficiency, an inherited form of emphysema; Phase I trials are underway with a potential product launch in early 2009. AGTC’s investors include Interwest Partners (Menlo Park, CA), Intersouth Partners (Durham, NC), MedImmune Ventures (Gaithersburg, MD), and Skyline Ventures (Palo Alto, CA). AGTC is collaborating with Genzyme to develop, manufacture and market a gene therapy product to treat Wet Age-Related Macular Degeneration. The Company is located in Gainesville, Florida in the University of Florida’s Sid Martin Biotechnology Development ( www.agtc.com )
Applied Genetic Technologies Corporation
12085 Research Drive
Alachua, Florida 32615
USA
Tel: (386) 462-2204
Fax: (386) 462-7396